Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC

NCT07103447 | Not Yet Recruiting Phase 2

• 1 other identifier: WestChinaL112
• Study Type: interventional
• Target: 54
• Locations: 0 countries
• Sites: N/A

Brief Summary

This prospective, multicenter, single-arm clinical study aims to evaluate the efficacy and safety of AK112 in combination with albumin-bound paclitaxel and carboplatin as neoadjuvant treatment in adult women with early or locally advanced triple-negative breast cancer (TNBC). The study seeks to address the pathological complete response (pCR) rate, objective response rate (ORR), breast conservation rate, and invasive disease-free survival (iDFS) following treatment with AK112 combined with albumin-bound paclitaxel and carboplatin in early or locally advanced TNBC.

Conditions

Breast Cancer - Female

Keywords

AK112 combining chemothrapy, neoadjuvant therapy, TNBC

Outcome Measures

Primary Outcomes (1)

• pCR

  pathological complete response

  After surgery, within an average of 2 weeks

Secondary Outcomes (1)

• ORR

  Two weeks after completing 6 cycles of neoadjuvant therapy (each cycle is 21 days)

Study Arms (1)

AK112 combining Nab-paclitaxel and carboplatin

EXPERIMENTAL

Drug: AK112, Carboplatin, Paxlitaxel

Interventions

AK112, Carboplatin, Paxlitaxel DRUG

The combination of AK112, a platinum-based chemotherapy agent, and Paxlitaxel is administered every three weeks as a neoadjuvant treatment for triple-negative breast cancer. After completing six cycles of this regimen, the participant undergoes surgical treatment.

AK112 combining Nab-paclitaxel and carboplatin

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary Participation and Informed Consent: The participant voluntarily agrees to join this clinical trial, signs a written informed consent form, understands the study, and is willing to comply with all trial procedures.
• Eligibility by Age and Gender: Female participants aged ≥18 years and ≤75 years on the day of signing the informed consent form.
• Pathological Confirmation of Disease: Histopathologically confirmed diagnosis of T1-4N0-3M0 (except for T1N0M0) triple-negative invasive breast cancer, defined as negative for estrogen receptor (ER) and progesterone receptor (PgR) (immunohistochemistry: ER, PR \< 1%), and human epidermal growth factor receptor 2 (HER2) (immunohistochemistry HER2 "0\~1+"; or immunohistochemistry HER2 "2+" with no amplification on HER2 FISH gene testing).
• Measurable Lesion: At least one lesion measurable according to RECIST v1.1 criteria. Participants diagnosed at an external institution agree to provide archived or freshly obtained tumor tissue samples (formalin-fixed paraffin-embedded \[FFPE\] tissue blocks or at least 25 unstained tumor tissue slides) for pathology review.
• Planned Surgical Treatment: Participants are scheduled to undergo definitive surgical resection of breast cancer, including either breast-conserving surgery or mastectomy, along with sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND), and are planned to receive neoadjuvant chemotherapy.

You may not qualify if:

• Prior Anti-Cancer Treatments.
• Received systemic anti-cancer treatment, including chemotherapy, radiotherapy, immunotherapy, targeted therapy (within 2 weeks for small molecule targeted therapies), or biological agent treatment within 4 weeks before enrollment.
• Received palliative local treatments within 2 weeks before enrollment.
• Received systemic non-specific immune modulatory treatments (e.g., interleukins, interferons, thymopeptides) within 2 weeks before enrollment.
• Received traditional Chinese medicine or Chinese patent medicines with anti-cancer indications within 2 weeks before enrollment.
• Prior PD-1/PD-L1 Treatment.
• Previously received treatment with PD-1 inhibitors or PD-L1 inhibitors.
• Concurrent Participation in Other Clinical Studies.
• Currently participating in another clinical study, unless it is an observational, non-interventional study or the follow-up period of an interventional study.
• History of Other Malignancies:
• (1) Has a history of other malignant tumors within 5 years prior to enrollment or concurrently, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, and thyroid cancer.
• (2) Active Autoimmune Diseases: Has active autoimmune diseases that required systemic treatment (such as corticosteroids) within 2 years before enrollment, or has autoimmune diseases that the investigator judges may recur or require planned treatment.

Sponsors & Collaborators

• Shuangyue Liu: lead

MeSH Terms

Interventions

Carboplatin

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals

Central Study Contacts

Ting Luo

CONTACT

86 +18980606230; luoting@wchscu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Chief physician

Study Record Dates

• First Submitted: January 17, 2025
• First Posted: August 5, 2025
• Study Start: September 10, 2025
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2028
• Last Updated: August 5, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share